BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35137934)

  • 21. Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series.
    Sollini M; Pasqualetti F; Perri M; Coraggio G; Castellucci P; Roncali M; Boni R; Lazzeri E; Galeandro M; Paiar F; Versari A; Erba PA
    Cancer Imaging; 2016 Aug; 16(1):27. PubMed ID: 27581366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study).
    Beheshti M; Kunit T; Haim S; Zakavi R; Schiller C; Stephens A; Dinkelborg L; Langsteger W; Loidl W
    Mol Imaging Biol; 2015 Jun; 17(3):424-33. PubMed ID: 25315836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
    Buchegger F; Garibotto V; Zilli T; Allainmat L; Jorcano S; Vees H; Rager O; Steiner C; Zaidi H; Seimbille Y; Ratib O; Miralbell R
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):68-78. PubMed ID: 24104592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
    Langsteger W; Balogova S; Huchet V; Beheshti M; Paycha F; Egrot C; Janetschek G; Loidl W; Nataf V; Kerrou K; Pascal O; Cussenot O; Talbot JN
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):448-57. PubMed ID: 21738117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer.
    Lamanna G; Tabouret-Viaud C; Rager O; Jorcano S; Vees HJ; Seimbille Y; Zaidi H; Ratib O; Buchegger F; Miralbell R; Zilli T; Garibotto V
    Clin Nucl Med; 2017 May; 42(5):e242-e246. PubMed ID: 28240662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pelvic dynamic acquisition on final reading of
    Latge A; Heimburger C; Severac F; Meyer N; Somme F; Imperiale A
    J Med Imaging Radiat Oncol; 2022 Apr; 66(3):324-331. PubMed ID: 34323005
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Kanoun S; Walker P; Vrigneaud JM; Depardon E; Barbier V; Humbert O; Moulin M; Créhange G; Cormier L; Loffroy R; Brunotte F; Cochet A
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):986-994. PubMed ID: 28333020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of 18F-fluorocholine PET/CT positive pulmonary lesions in prostate cancer patients.
    Rager O; Baskin A; Amzalag G; Buchegger F; Miralbell R; Ratib O; Zilli T; Garibotto V
    Nuklearmedizin; 2015; 54(5):211-6. PubMed ID: 26213186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
    Tong AK; Zhang ZX; Zaheer S; Yan XS
    Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How we read FCH-PET/CT for prostate cancer.
    Beauregard JM; Beaulieu A
    Cancer Imaging; 2016 Dec; 16(1):41. PubMed ID: 27923396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid lymphoma incidentally detected by 18F-fluorocholine (FCH) PET/CT.
    Eccles A; Challapalli A; Khan S; Barwick T; Mangar S
    Clin Nucl Med; 2013 Sep; 38(9):755-7. PubMed ID: 23856826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
    Kwee SA; Wei H; Sesterhenn I; Yun D; Coel MN
    J Nucl Med; 2006 Feb; 47(2):262-9. PubMed ID: 16455632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
    Balogova S; Huchet V; Kerrou K; Nataf V; Gutman F; Antoine M; Ruppert AM; Prignon A; Lavolée A; Montravers F; Mayaud C; Cadranel J; Talbot JN
    Nucl Med Commun; 2010 May; 31(5):389-97. PubMed ID: 20145579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.
    Kwee SA; Coel MN; Lim J
    Ann Nucl Med; 2012 Jul; 26(6):501-7. PubMed ID: 22549847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
    Evangelista L; Cimitan M; Hodolič M; Baseric T; Fettich J; Borsatti E
    Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of hormonal therapy in prostate cancer patients undergoing [18F]fluoromethyl choline PET/CT: a retrospective study.
    Palumbo B; Sivolella S; Palumbo I; Buresta T; Radicchia V; Fravolini ML; Ferretti F; Bellavita R; Mearini L; Scialpi M; Aristei C; Pelliccia G
    Q J Nucl Med Mol Imaging; 2016 Dec; 60(4):397-403. PubMed ID: 25017896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.